Aminoglycoside Resistance Mechanisms in Bacterial Pathogens

Aminoglycosides are potent bactericidal agents that act by binding to the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. The therapeutic utility of this class has been increasingly compromised by diverse resistance mechanisms. The principal routes to resistance encompass enzymatic modification of the antibiotic, alteration of the ribosomal target, active efflux and impaired uptake. Enzymatic modification is the most widespread mechanism and involves aminoglycoside-modifying enzymes—acetyltransferases, phosphotransferases and nucleotidyltransferases—that chemically inactivate the drug. Methylation of the 16S rRNA binding site prevents antibiotic docking and confers high-level resistance, often mediated by plasmid-borne methyltransferases. Decreased intracellular concentration of aminoglycosides arises through overexpression of efflux pumps and changes in membrane permeability, particularly in Gram-negative organisms. Target alterations via mutations in ribosomal proteins and rRNA further contribute to reduced binding affinity. Horizontal gene transfer, frequently via plasmids, transposons and integrons, accelerates the global dissemination of resistance determinants. The clinical impact of these mechanisms is profound; treatment failures and increased mortality rates in severe infections underscore an urgent need for novel inhibitors, semisynthetic derivatives with improved resistance profiles, and combination therapies that restore aminoglycoside efficacy.

Research from Nature Portfolio

A seminal structural study has demonstrated how chemical modification at the 4′-position of the deoxystreptamine ring can enhance selectivity for bacterial over eukaryotic ribosomes. Through systematic synthesis of 4′-O-ether and acetal derivatives and evaluation against mutant and wild-type ribosomes, researchers identified compounds that retain potent inhibition of bacterial translation while exhibiting negligible binding to mitochondrial and cytosolic human ribosomes. This work establishes a blueprint for designing next-generation aminoglycosides that circumvent toxicity and evade selectivity-based resistance by exploiting subtle differences in the ribosomal drug-binding pockets.

Aminoglycoside Resistance Mechanisms in Bacterial Pathogens publication trend

The graph below shows the total number of articles in aminoglycoside resistance mechanisms in bacterial pathogens across all publications each year (not limited to Nature Index journals).

Technical terms

Aminoglycoside-modifying enzyme: An enzyme that chemically alters aminoglycosides (by acetylation, phosphorylation or adenylation) to inactivate the antibiotic.

16S rRNA methyltransferase: An enzyme that methylates the 16S rRNA at the aminoglycoside binding site, preventing antibiotic interaction.

Efflux pump: A membrane-embedded transport protein that expels antibiotics from the bacterial cell to reduce intracellular drug concentration.

Target modification: Genetic alterations in ribosomal proteins or rRNA that reduce aminoglycoside binding affinity.

References

1. Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions. Antibiotics (2021).
2. 4′-O-substitutions determine selectivity of aminoglycoside antibiotics. Nature Communications (2014).
3. Synthesis of 6″-Modified Kanamycin A Derivatives and Evaluation of Their Antibacterial Properties. Pharmaceutics (2023).
4. aac(6’)-Iaq, a novel aminoglycoside acetyltransferase gene identified from an animal isolate Brucella intermedia DW0551. Frontiers in Cellular and Infection Microbiology (2025).
5. Antibiotic Combination Therapy: A Strategy to Overcome Bacterial Resistance to Aminoglycoside Antibiotics. Frontiers in Pharmacology (2022).